Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tranilast + allopurinol
- Development stage
- Phase 2
- Lead developer
- Nuon Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tranilast + allopurinol is a fixed-dose oral combination of two small molecule drugs developed for the treatment of gout and hyperuricemia. Tranilast is an anthranilic acid derivative with uricosuric and anti-inflammatory properties, acting primarily by inhibiting major reabsorptive urate transporters such as SLC22A12 protein (URAT1), SLC2A9 protein (GLUT9), OAT4, and OAT10, leading to increased excretion of uric acid[4]. It also has immunomodulatory effects and can inhibit the NLRP3 inflammasome[5]. Allopurinol is a purine analog that acts as a xanthine oxidase inhibitor to reduce the production of uric acid in the body[6][8]. The combination was intended to provide dual mechanisms for lowering serum urate levels—by both reducing production (allopurinol) and increasing excretion (tranilast). The product was developed by Nuon Therapeutics under the code name NU-1618 but development was discontinued after phase 2 trials for gout and hyperuricemia[2].
- Brand names
- Combination 400Combination400Combination-400
- Other names
- tranilast/allopurinol
02
Targets
NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)OAT4 (Solute carrier family 22 member 11)URAT1 (Uric Acid Transporter 1)OAT10 (Solute carrier family 22 member 13)GLUT9 (Glucose transporter type 9)SMCT1 (Sodium-coupled monocarboxylate transporter 1)XO (Xanthine Oxidoreductase)
Beyond the preview
Go deeper on Tranilast + allopurinol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tranilast + allopurinol.